Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2016

View Archived Issues

Primex Pharmaceuticals licenses oral solution for pediatric anesthesia from Advicenne

Boehringer Ingelheim and Hydra Biosciences disclose TrpC5 inhibitors

Merck & Co. patents free fatty acid receptor 1 agonists

Pharmacyclics introduces BTK inhibitors

First patient dosed in phase IIa study of factor VIIa-CTP for the treatment of hemophilia

4DMT and CRF partner to develop gene therapy treatment for choroideremia

Neutrophil elastase inhibitors described in Boehringer Ingelhiem patents

Vaginal ring containing dapivirine reduces the risk of HIV-1 infection among African women

Myriad and AbbVie expand strategic research collaboration

ViiV Healthcare completes acquisition of Bristol-Myers Squibb HIV R&D portfolio

Sanofi to return U.S. and Canadian rights for Auvi-Q to kaleo

Positive topline results from phase I trial of SOR-C13 in patients with advanced solid tumors

Novo Nordisk reports results from third phase IIIa trial of semaglutide in type 2 diabetes

FDA approves Ibrance for new metastatic breast cancer indication

Galunisertib plus lomustine not superior to monotherapies in phase II glioblastoma study

Promising phase II results for AdV-tk plus valacyclovir adjuvant to SOC in malignant glioma

OncBioMune reports phase I results for prostate cancer vaccine ProscaVax

FDA refuses to file PTC Therapeutics' NDA for ataluren

Novan initiates phase III program of SB-204 for acne

New study to explore utility of ambroxol for Parkinson's disease

First U.S. hospital-based rapid test for the Zika virus now available

ImmunID signs master collaboration agreement with MSK to validate ImmunTraCkeR utility

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...